Skip to main content
Skip to section navigation
Skip to footer
About Us
Company Overview
Management
Board of Directors
Pipeline
Pipeline Overview
Paxalisib
PD-L1 Protein Degrader
SETDB1 Inhibitor
EVT801
Clinical Trials
Posters & Publications
Technology
Media Center
Media Center Overview
News
Events
In The News
Video Gallery
ASX Announcements
Investors
Investors Overview
News & Events
Company Info
Financial Results
Stock Data
SEC Filings
Governance
ASX Delisting
Contact Us
ASX Announcements
Media Center
Media Center
Media Center Overview
News
Events
In The News
Video Gallery
ASX Announcements
Jun 24, 2022
Cleansing notice
Jun 23, 2022
Change in substantial holding
Jun 23, 2022
Kazia presentation on paxalisib for childhood brain cancer
Jun 17, 2022
FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT
Jun 17, 2022
Application for quotation of securities - KZA
Jun 17, 2022
Cleansing Notice
Jun 14, 2022
Kazia paxalisib preclinical DIPG data released at IPSNO
Jun 10, 2022
Application for quotation of securities - KZA
Jun 10, 2022
Cleansing notice
Jun 8, 2022
Kazia's Alliance study progresses to expansion phase
rss_feed
RSS
Previous Page
arrow_back
Page
1
…
Page
10
Page
11
Page
12
Page
13
Page
14
Page
15
Page
16
Page
17
Page
18
Page
19
Next Page
arrow_forward
Select a page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
